CN112353847A - Plant emulsion for treating soft tissue injury after exercise and preparation method thereof - Google Patents

Plant emulsion for treating soft tissue injury after exercise and preparation method thereof Download PDF

Info

Publication number
CN112353847A
CN112353847A CN202011321031.9A CN202011321031A CN112353847A CN 112353847 A CN112353847 A CN 112353847A CN 202011321031 A CN202011321031 A CN 202011321031A CN 112353847 A CN112353847 A CN 112353847A
Authority
CN
China
Prior art keywords
extract
mint
soft tissue
tissue injury
emulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011321031.9A
Other languages
Chinese (zh)
Inventor
汪涛
姚霖
陈阁
高锦明
汤江江
刘瑞
侯建强
李艳
冯博
许睿
章志强
盛伟伟
李庆
孙克慧
张宁
柴恒
赵华
黄强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shaanxi Institute Of Sports Science
Original Assignee
Shaanxi Institute Of Sports Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shaanxi Institute Of Sports Science filed Critical Shaanxi Institute Of Sports Science
Priority to CN202011321031.9A priority Critical patent/CN112353847A/en
Publication of CN112353847A publication Critical patent/CN112353847A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534Mentha (mint)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/37Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a plant emulsion for treating soft tissue injury after sports and a preparation method thereof, wherein the plant emulsion comprises the following components in percentage by weight: 5-15% of a holly extract, 1-6% of a mint extract, 15-20% of polyoxyethylene hydrogenated castor oil, 0.5-3% of isopropyl myristate, 1-5% of 1, 3-butanediol and 51-77.5% of water.

Description

Plant emulsion for treating soft tissue injury after exercise and preparation method thereof
Technical Field
The invention belongs to the technical field of percutaneous penetration, and particularly relates to a plant emulsion for treating soft tissue injury after exercise and a preparation method thereof.
Background
The soft tissue injury is a disease which is frequently occurred in sports and training of athletes, the soft tissue injury after sports refers to a series of soft tissue injuries of muscles, ligaments, tendons, blood vessels and the like caused by sports extrusion, traction or long-time load, and is a common disease in orthopedics. Soft tissue injury can cause swelling, pain, and limited joint movement, which can cause significant damage to the joints of the human body if the patient is not treated in a timely manner.
The joint stability is damaged due to soft tissue injury, and the joint stability is damaged, namely, soft tissue and tendon fibers at the joint are torn and cannot be repaired due to dislocation and the like seen in daily life, so that symptoms caused by the dislocation and the like can be caused after the next exercise. The stability of the joint is affected because after injury, the elasticity of many soft tissues is affected, and the joint itself is in a more relaxed state, especially in patients who have not been effectively treated. Consequently, these soft tissues do not provide fixation to the adjacent bone joints, resulting in reduced joint stability. Even more, it induces traumatic arthritis. If the treatment is not timely after the soft tissue injury occurs, ligament rupture symptoms easily appear, and after the symptoms are long, the symptoms easily cause the generation of the injury arthritis. The symptoms are mostly seen in some synovial tissue injuries, because the injuries are not effectively treated, and the functions of the synovial tissue are affected to reduce the absorption capacity of joint fluid, so that hydrops appears in joint cavities.
At present, various medicines for treating soft tissue injury comprise external products such as plaster, Yunnan white drug powder, sitagliptin and the like, and the plaster and the Yunnan white drug powder have the following principles: 1. containing a plant anesthetic for relieving pain by paralyzing nerve endings, 2, a plant antibiotic: such as topical anti-inflammatory matrine; the defects are as follows: 1. a large amount of plant anesthetic has liver and kidney injury and is poisoned by large dose use; 2. the large molecular weight can not effectively permeate into the muscle and the joint capsule cavity tissue, and the treatment from the root is difficult. The theory of the sitagliptin is that the non-steroidal anti-inflammatory drugs such as diclofenac sodium can realize pain relieving and anti-inflammation, and the defects are as follows: 1. the molecular weight is too large to pass through a defense layer of the skin, the use needs repeated kneading to open local skin gaps to take effect, and the effect is too slow; 2. because the local penetration and the skin defense problem are not considered in the formula and the process, the use is troublesome, the local kneading is generally needed for 1 to 2 hours to take effect, and the number of the penetration layers is too small, and the treatment period is too long.
Because the skin has a natural barrier, the active ingredients of the existing formula have low permeability and insufficient bioavailability, and effective blood concentration is difficult to form at the local part of a focus to achieve an ideal treatment effect; and some formulas have the problems of complex raw material components, illegal anesthetic components application and high preparation cost, and some traditional Chinese medicines have slow treatment process and unsatisfactory effect.
Disclosure of Invention
The invention aims to overcome the defects of the prior art, provides the plant emulsion for treating the soft tissue injury after sports and the preparation method thereof, and solves the problems of poor effect, complex original components, application of illegal anesthetic components, high manufacturing cost and the like caused by low formula permeability and insufficient bioavailability in the prior art.
In order to solve the technical problem, the technical scheme of the invention is as follows: a plant emulsion for treating soft tissue injury after exercise comprises the following components in percentage by weight: 5-15% of a holly extract, 1-6% of a mint extract, 15-20% of polyoxyethylene hydrogenated castor oil, 0.5-3% of isopropyl myristate, 1-5% of 1, 3-butanediol and 51-77.5% of water.
Preferably, the weight percentage of each component is as follows: 8-12% of a holly extract, 2-5% of a mint extract, 16-18% of polyoxyethylene hydrogenated castor oil, 0.5-2% of isopropyl myristate, 1-4% of 1, 3-butanediol and 59-72.5% of water.
Preferably, the weight percentage of each component is as follows: 10% of holly extract, 3.5% of mint extract, 17% of polyoxyethylene hydrogenated castor oil, 1% of isopropyl myristate, 3% of 1, 3-butanediol and 65.5% of water.
Preferably, the preparation method of the holly extract comprises the following steps: selecting fresh Chinese ilex leaves, cleaning, draining and slicing the Chinese ilex leaves, soaking the Chinese ilex leaves in distilled water serving as a solvent for 10-12 hours, then carrying out steam distillation on the solution in which the Chinese ilex leaves are soaked for 1-2 hours, layering the liquid obtained after the steam distillation, collecting an oil layer, carrying out reduced pressure distillation on the oil layer at the distillation pressure of 0.09MPa, collecting fractions at the temperature of 218-224 ℃ to obtain a Chinese ilex extract, placing the Chinese ilex extract in a brown sample bottle, and storing at the temperature of 4 ℃.
Preferably, the material ratio of the Chinese ilex leaves to the water is 1: 1.
preferably, the preparation method of the mint extract comprises the following steps: selecting the overground part of mint, cleaning, draining and slicing the overground part of mint, drying to ensure that the water content is less than 8%, crushing the dried overground part of mint by using a crusher, sieving to obtain mint powder, filling the mint powder into an extraction kettle, and performing supercritical CO extraction2Extracting, collecting extract, placing the extract in brown bottle, and storing at 4 deg.C.
Preferably, the supercritical CO2The extraction pressure is 8-10 MPa, the temperature is 50-55 ℃, and CO is added2The flow rate is 22-25L/h, and the extraction time is 1-3 h.
Preferably, the preparation method of the plant emulsion for treating soft tissue injury after sports comprises the following steps:
step 1) dissolving 0.5-3% of isopropyl myristate, 5-15% of holly extract and 1-6% of mint extract in 15-20% of polyoxyethylene hydrogenated castor oil, and uniformly stirring until the mixture is completely mixed, wherein the reaction temperature is 43 ℃;
step 2) when the mixture in the step 1) is completely dissolved to be clear, adding the mixture into 51-77.5% of water, uniformly stirring, simultaneously adding 1-5% of 1, 3-butanediol, stirring, heating to 43 ℃, and pressurizing for reaction;
and 3) starting a cold cycle to cool the mixture obtained in the step 2) to 20 ℃, and keeping the whole temperature stable at 23 ℃ after the mixture is continuously cooled for 15-20 minutes to obtain the plant emulsion for treating the soft tissue injury after sports.
Preferably, the stirring speed in the step 1) is 40 times/minute, the stirring time is 50-60 minutes, the stirring speed in the step 2) is 40 times/minute, the stirring time is 30-60 minutes, and the pressurizing pressure is 897 bar.
Compared with the prior art, the invention has the advantages that:
(1) according to the invention, the ilex extract and the mint extract are selected as main effective components, isopropyl myristate is used as an emulsifier, 1, 3-butanediol is used as an auxiliary emulsifier, and polyoxyethylene hydrogenated castor oil is used as an oil phase;
(2) according to the invention, the ilex extract, the mint extract and isopropyl myristate are dissolved in polyoxyethylene hydrogenated castor oil, then the mixed oil phase, the 1, 3-butanediol and water are mixed for high-pressure emulsification treatment, and after emulsification is finished, the temperature is rapidly reduced, and a water-in-oil structure is formed by temperature phase control, so that the plant emulsion disclosed by the invention is simple in preparation method, simple in preparation method and low in preparation cost, and the activity of effective components is ensured by low-temperature preparation;
(3) the plant emulsion is of a water-in-oil structure, the water-in-oil structure can pull effective molecules open, the effective molecules are prevented from being adhered to form macromolecules due to van der Waals force, a single water-in-oil structure has small molecules, only dozens of nanometers to dozens of nanometers, the water-in-oil structure can rapidly permeate layer by layer through skin, wall breaking is carried out on the focus to enable the effective molecules to act on the focus, the treatment effect is good, the treatment process is fast, and the bioavailability is high;
(4) the active ingredients of the plant emulsion are a wintergreen extract and a mint extract, the main active ingredients of the wintergreen extract are salicylic acid and salicylic acid glycoside, the main active ingredients of the mint extract are menthol and menthone, the high-purity salicylic acid substance has anti-inflammatory and pain-relieving effects, the salicylic acid plays an analgesic effect by inhibiting the synthesis of a local nerve ending transmitter prostaglandin E, the high-purity menthol has high volatility, and the high-purity menthol takes away local tissue heat in the local use volatilization process so as to reduce local temperature, can reduce local tissue exudation after local temperature reduction, and simultaneously reduces nerve ending sensitivity to cooperate with the salicylic acid substance to play an analgesic function; meanwhile, the NE (microemulsion) technology is used for reducing the particle diameters of two effective substances so that the two effective substances can directly penetrate through the natural barrier of the skin to the dermis and even the joint capsule cavity, thus playing the roles of deep pain relieving and anti-inflammatory and avoiding the adverse reaction brought by the application of simple aconitine, ephedrine and anesthetic;
(5) menthol in the mint extract serving as the effective component of the plant emulsion can volatilize layer by layer in the penetration, and continuously volatilizes after penetrating to a deep focus to realize the function of locally and deeply cooling, so that the temperature of the local surface and depth is durably reduced, the sensitivity of local nerve endings is reduced, and the rapid pain relieving is realized.
Detailed Description
The following describes embodiments of the present invention with reference to examples:
well-known structures or functions may not be described in detail in the following embodiments in order to avoid unnecessarily obscuring the details. Unless defined otherwise, technical and scientific terms used in the following examples have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
Example 1
The invention discloses a plant emulsion for treating soft tissue injury after sports, which comprises the following components in percentage by weight: 5-15% of a holly extract, 1-6% of a mint extract, 15-20% of polyoxyethylene hydrogenated castor oil, 0.5-3% of isopropyl myristate, 1-5% of 1, 3-butanediol and 51-77.5% of water.
Example 2
Preferably, the weight percentage of each component is as follows: 8-12% of a holly extract, 2-5% of a mint extract, 16-18% of polyoxyethylene hydrogenated castor oil, 0.5-2% of isopropyl myristate, 1-4% of 1, 3-butanediol and 59-72.5% of water.
Preferably, the weight percentage of each component is as follows: 10% of holly extract, 3.5% of mint extract, 17% of polyoxyethylene hydrogenated castor oil, 1% of isopropyl myristate, 3% of 1, 3-butanediol and 65.5% of water.
Example 3
Preferably, the preparation method of the holly extract comprises the following steps: selecting fresh Chinese ilex leaves, cleaning, draining and slicing the Chinese ilex leaves, soaking the Chinese ilex leaves in distilled water serving as a solvent for 10-12 hours, then carrying out steam distillation on the solution in which the Chinese ilex leaves are soaked for 1-2 hours, layering the liquid obtained after the steam distillation, collecting an oil layer, carrying out reduced pressure distillation on the oil layer at the distillation pressure of 0.09MPa, collecting fractions at the temperature of 218-224 ℃ to obtain a Chinese ilex extract, placing the Chinese ilex extract in a brown sample bottle, and storing at the temperature of 4 ℃.
Preferably, the material ratio of the Chinese ilex leaves to the water is 1: 1.
example 4
Preferably, the preparation method of the mint extract comprises the following steps: selecting the overground part of mint, cleaning, draining and slicing the overground part of mint, drying to ensure that the water content is less than 8%, crushing the dried overground part of mint by using a crusher, sieving to obtain mint powder, filling the mint powder into an extraction kettle, and performing supercritical CO extraction2Extracting, collecting extract, placing the extract in brown bottle, and storing at 4 deg.C.
Preferably, the supercritical CO2The extraction pressure is 8-10 MPa, the temperature is 50-55 ℃, and CO is added2The flow rate is 22-25L/h, and the extraction time is 1-3 h.
Example 5
Preferably, the preparation method of the plant emulsion for treating soft tissue injury after sports comprises the following steps:
step 1) dissolving 0.5-3% of isopropyl myristate, 5-15% of holly extract and 1-6% of mint extract in 15-20% of polyoxyethylene hydrogenated castor oil, and uniformly stirring until the mixture is completely mixed, wherein the reaction temperature is 43 ℃;
step 2) when the mixture in the step 1) is completely dissolved to be clear, adding the mixture into 51-77.5% of water, uniformly stirring, simultaneously adding 1-5% of 1, 3-butanediol, stirring, heating to 43 ℃, and pressurizing for reaction;
and 3) starting a cold cycle to cool the mixture obtained in the step 2) to 20 ℃, and keeping the whole temperature stable at 23 ℃ after the mixture is continuously cooled for 15-20 minutes to obtain the plant emulsion for treating the soft tissue injury after sports.
Preferably, the stirring speed in the step 1) is 40 times/minute, the stirring time is 50-60 minutes, the stirring speed in the step 2) is 40 times/minute, the stirring time is 30-60 minutes, and the pressurizing pressure is 897 bar.
The following contents are all weight percentages.
Example 6
1kg of plant emulsion is prepared, and the content of each component of the plant emulsion is as follows:
8% of wintergreen extract, 5% of mint extract, 16% of polyoxyethylene hydrogenated castor oil, 2% of isopropyl myristate, 1, 3-butanediol and 68% of water.
Preparing a holly extract:
selecting fresh Chinese ilex leaves, cleaning, draining and slicing the Chinese ilex leaves, and soaking the Chinese ilex leaves in distilled water serving as a solvent, wherein the material ratio of the Chinese ilex leaves to water is 1: 1, soaking for 10 hours, then carrying out steam distillation on the solution soaked with the ilex purpurea Hassk leaves, keeping the solution in a vacuum environment, wherein the distillation time is 1 hour, collecting an oil layer after liquid obtained after the steam distillation is layered, carrying out reduced pressure distillation on the oil layer, wherein the distillation pressure is 0.09MPa, collecting fractions at 218-224 ℃, repeatedly extracting once again to obtain a ilex purpurea Hassk extract, placing the ilex purpurea Hassk extract in a brown sample bottle, and storing at 4 ℃.
The ilex extract is detected by gas chromatography, the gas chromatography detection meets the SNT-0513 standard, and the purity of the effective components is more than 99%.
Preparing a mint extract:
selecting the overground part of mint, cleaning, draining and slicing the overground part of mint, drying to ensure that the water content is less than 8%, crushing the dried overground part of mint by using a crusher, sieving to obtain mint powder, filling the mint powder into an extraction kettle, and performing supercritical CO extraction2Extracting under the conditions of extraction pressure of 9.2MPa, temperature of 51 ℃ and CO2Controlling the flow rate at 24.8L/h, extracting for about 1.5h, collecting and extracting to obtain herba Menthae extractThe mint extract was placed in a brown sample bottle and stored at 4 ℃.
Detecting the herba Menthae extract by gas chromatography to obtain menthol crystal of 300 mg-1, RSD of 1%, and purity of effective components of more than 99%.
Preparing a plant emulsion:
step 1) weighing 16% of polyoxyethylene hydrogenated castor oil, adding 2% of isopropyl myristate, 8% of wintergreen extract and 5% of mint extract into an oil phase cabin, setting the temperature at 43 ℃ and the rotating speed at 60/min for 1h, adding 2% of isopropyl myristate, 8% of wintergreen extract and 5% of mint extract into the oil phase cabin to start working when the temperature of the polyoxyethylene hydrogenated castor oil reaches 43 ℃, and observing the appearance of the oil phase until the oil phase is clear and uniformly mixed after the working time reaches 1 h;
step 2) sucking the oil phase obtained in the step 1) into an ultrahigh pressure mixing tank, adding 1% of co-emulsifier 1, 3-butanediol in the sucking process, preparing 68% of ultrapure deionized water in advance in a main tank body, heating to 43 ℃ and setting the pressure to 897bar, adding the ultrapure deionized water into the high pressure mixing tank, adopting oil injection of 1L per minute in the sucking process, starting stirring and pressurizing emulsification treatment, and continuing for 30min and then continuing for emulsification for about 45 min;
and 3) starting a cold cycle to cool the mixture obtained in the step 2) to 20 ℃, keeping the temperature of the whole mixture at 23 ℃ after 15 minutes, obtaining the plant emulsion for treating soft tissue injury after exercise, and discharging about 0.1L of finished raw materials at a discharge hole for coarse inspection.
The results of the coarse inspection are as follows:
physical properties of naked eyes: colorless and clear.
Odor: mint flavor with green winter taste.
Direct measurement: the pH value is 5.5-7.
The characteristics are as follows: and (4) oiliness.
Quickly freezing 100ml of plant emulsion to-10-20 deg.C, freezing the plant emulsion, and quickly thawing to 40 deg.C to observe properties without change.
And (5) observing the stability and the stability of the emulsion in a high-speed oscillation experiment for 30 min.
The HLB value (hydrophilic-lipophilic balance) is between 8 and 12.
Example 7
1kg of plant emulsion is prepared, and the content of each component of the plant emulsion is as follows:
12% of wintergreen extract, 2% of mint extract, 18% of polyoxyethylene hydrogenated castor oil, 0.5% of isopropyl myristate, 4% of 1, 3-butanediol and 63.5% of water.
The preparation method is the same as example 6.
Example 8
1kg of plant emulsion is prepared, and the content of each component of the plant emulsion is as follows:
5% of wintergreen extract, 6% of mint extract, 15% of polyoxyethylene hydrogenated castor oil, 3% of isopropyl myristate, 5% of 1, 3-butanediol and 66% of water.
The preparation method is the same as example 6.
Example 9
1kg of plant emulsion is prepared, and the content of each component of the plant emulsion is as follows:
15% of wintergreen extract, 1% of mint extract, 20% of polyoxyethylene hydrogenated castor oil, 2% of isopropyl myristate, 3% of 1, 3-butanediol and 59% of water.
The preparation method is the same as example 6.
Example 10
1kg of plant emulsion is prepared, and the content of each component of the plant emulsion is as follows:
10% of holly extract, 3.5% of mint extract, 17% of polyoxyethylene hydrogenated castor oil, 1% of isopropyl myristate, 3% of 1, 3-butanediol and 65.5% of water.
The preparation method is the same as example 6.
Comparative example 1
Currently, norwalk-sitagliptin, switzerland is purchased in the market.
Comparative example 2
Yunnan Baiyao, commercially available.
Comparative example 3
The japanelin pharmaceutical diclofenac sodium patch is commercially available.
Performance detection
1. And (3) particle diameter detection: the particle diameter of the embodiment 6-10 of the invention is less than 50nm, and the detection mechanism comprises: the institute of pharmaceutical and chemical industry, national academy of sciences.
2. The invention carries out bacteriostasis test, compares the examples 6-10 with the comparative examples 1-3, and has the following contents:
2.1 test procedure
The bacteriostasis test mainly adopts a bacteriostasis ring method to test the bacteriostasis effect of the plant emulsion on staphylococcus aureus, escherichia coli and candida albicans, and the specific test method comprises the following steps:
(1) activating strains: transferring escherichia coli, staphylococcus aureus, candida albicans and lactobacillus stored in a refrigerator at 4 ℃ onto a fresh nutrient agar slant, and culturing for 18-24 hours at 37 ℃.
(2) Preparation of bacterial suspension: washing thallus Porphyrae on the inclined plane with 10mL sterilized normal saline twice, placing in conical flask containing glass beads, shaking on shaking table at 200r/min for 10min, and adjusting the concentration of bacterial suspension to 106cfu/ml。
(3) Preparing a bacteriostatic flat plate: subpackaging 20ml of melted nutrient agar culture medium in each test tube, wiping off excess culture medium at the opening of the test tube with a paper towel, adding a rubber stopper, binding 7 tubes in a bundle, sterilizing at 121 ℃ for 20min, slightly cooling, and placing in a 50 ℃ constant-temperature water bath for heat preservation. On a clean bench, 1mL of bacterial suspension is added into each sterilized culture dish, then the bacterial suspension is poured into a 20mL culture dish, the bacterial suspension and the culture dish are fully mixed, condensed water is dried, and the bacterial suspension is solidified.
(4) Oxford cup method: and (3) taking out the sterilized Oxford cup by using sterile forceps, putting the sterilized Oxford cup on the flame of an alcohol burner, quickly passing a fire, vertically placing the surface of the culture medium, and slightly pressing to ensure that no gap exists between the bottom of the cup and the culture medium. Placing 5 Oxford cups on each plate, injecting 200uL of gel into each Oxford cup, and using normal saline as a reference in the middle, wherein the plant latex cannot overflow; each plant emulsion is subjected to 3 times of repeated culture at 37 ℃ for 24 hours, the diameter of the inhibition zone is observed, measured and recorded, and the test result is shown in table 1.
TABLE 1 results of bacteriostatic tests in examples 6-10 and comparative examples 1-3
Figure BDA0002792913790000111
As can be seen from Table 1, the plant emulsions in the examples 6 to 10 have good bacteriostatic effects on Escherichia coli, Staphylococcus aureus and Candida albicans, wherein the diameter of the bacteriostatic ring is larger than 12mm, the bacteriostatic requirements are met, the bacteriostatic rates in 5 to 10min are 99.9%, the bacteriostatic effects in the comparative examples 1 to 2 are poor, and the bacteriostatic effect in the comparative example 3 is general.
3. One-time skin mucosal irritation test
The invention carries out a skin mucosa stimulation test for one time, and the content is as follows:
3.1 test procedure
1) Selecting 6 common-grade rabbits, 3 female rabbits and 3 male rabbits with the weight of 2 kg-3 kg, randomly dividing the rabbits into an experimental group and a control group, wherein each group comprises 3 rabbits;
2) a blunt tube of about 8cm is connected with a 2mL syringe, and the syringe and the catheter are filled with the test substance for standby, and one set is prepared for each animal. The animal is fixed on the back, the nasal cavity is exposed, the head of the catheter is wetted by the contrast solution and then is inserted into the nasal cavity mucosa for 4-5 cm gently, 2mL of a test object (plant emulsion, example 10) is injected slowly by a syringe, and then the catheter is pulled out, so that the contamination is completed. Control animals were treated with saline as well.
3) 24h after the infection, the animals are killed by an air embolism method, the complete nasal cavity mucosa tissue is taken out after laparotomy, and the longitudinal incision is carried out to observe whether congestion, edema and other manifestations exist. Then, the nasal mucosa tissues are put into 10% formalin solution for fixation for more than 24h, 3 parts of the nasal mucosa are selected for tissue slice making, and histopathological examination is carried out after HE staining.
4) Evaluation of results the evaluation of the irritation response intensity was carried out by grading the irritation response intensity of the mucous membrane according to the evaluation standard of primary irritation response in 2002 edition "Disinfection technical Specification".
3.2 analysis of results
1) And (4) visual observation: under the test condition, the nasal mucosa of the animals in the test group and the animals in the control group have no obvious phenomena of congestion, edema and the like.
2) The histopathological examination results (test rabbit nasal mucosa irritation test response scores) are shown in table 2:
TABLE 2 test substance rabbit nasal mucosa irritation test response score
Figure BDA0002792913790000121
As can be seen from Table 2, the irritation index of the plant emulsion of the present invention (example 10) to the nasal mucosa of rabbits was 1.11, and the irritation response intensity was very slight irritation, which all met the specified range.
4. Observation of clinical effects
4.1 case data
The applicant collects 136 cases of acute and chronic exercise injury patients (acute and chronic) in sports hospitals in Shaanxi province during 9-2020 and 11-2020, the selection standards of the patients are not fracture, bone fissure, muscle and ligament laceration and local open injury, the patients are divided into 4 groups, 34 patients in each group use sitalin (the current global main stream treatment standard, Beijing Nowa), 2 groups use Yunnan white drug powder aerosol, 3 groups use Japan Xiaolin pharmaceutical diclofenac sodium paste, 4 groups use the plant emulsion, the age is 18-50 years, and the course of disease is 1 hour-3 years.
4.2 methods of treatment
The treatment effect of the treated object is determined by the joint muscle activity and local swelling condition of the treated object 3 times a day. The method selects the common acute and chronic injuries, considers the injury of the human body structure from the surface layer injury to the deep part injury by combining the injury condition, and comprehensively evaluates the real curative effect.
4.3 therapeutic criteria
And (3) healing: the symptoms disappear, and the local movement of the joint is not limited.
The method has the following advantages: the symptoms are obviously improved, the local part hardly has red swelling, no pressing pain and slightly limited local activity.
And (4) invalidation: pain, local red swelling, limited movement and no improvement.
The effective rate and the cure rate are calculated according to the cure and effective case number.
The treatment period is calibrated according to disease types, and the disease types are shown in a table 3:
TABLE 3 treatment period for each disease category
Figure BDA0002792913790000131
Figure BDA0002792913790000141
Evaluation criteria: is ineffective, effective and cured.
4.4 analysis of results
Example results analysis, results of 34 persons in the nataline (norwalk, switzerland) treatment group are shown in table 4:
TABLE 4 treatment results of 34 persons in the L-sitalin (Nuohua, Switzerland) treatment group
Figure BDA0002792913790000142
Evaluation of curative effect ratio:
the sitagliptin is a product for treating sports injury and injury pain of muscles, joints, fascia and ligaments, which is produced by Nuohua of Swiss, and is ranked the first in the industry at present.
Acute joint sprain: the effective rate (1 hour +72 hours) is 0 percent;
acute muscle strain: the effective rate (1 hour +72 hours) is 100 percent, and the cure rate (1 hour +72 hours) is 0 percent;
chronic achilles tendonitis: the effective rate (7 days +14 days) is 0 percent, and the cure rate (7 days +14 days) is 0 percent;
chronic bursitis: the effective rate (7 days +14 days) is 0 percent, and the cure rate (7 days +14 days) is 0 percent;
chronic fasciitis: the effective rate (7 days +14 days) is 50%, and the cure rate (7 days +14 days) is 0%.
34 of the Yunnan Baiyao aerosol treatment group are shown in Table 5:
TABLE 5 therapeutic results of 34 Yunan Baiyao Aerosol treatment groups
Figure BDA0002792913790000151
Evaluation of curative effect ratio:
the Yunnan Baiyao aerosol is a product for treating diseases such as muscle, joint, fascia and ligament injury pain, arthritis and the like, which are produced by Yunnan Baiyao GmbH.
Acute joint sprain: the effective rate (1 hour +72 hours) is 25 percent, and the cure rate (1 hour +72 hours) is 0 percent;
acute muscle strain: the effective rate (1 hour +72 hours) is 100 percent, and the cure rate (1 hour +72 hours) is 0 percent;
chronic achilles tendonitis: the effective rate (7 days +14 days) is 0 percent, and the cure rate (7 days +14 days) is 0 percent;
chronic bursitis: the effective rate (7 days +14 days) is 0 percent, and the cure rate (7 days +14 days) is 0 percent;
chronic fasciitis: the effective rate (7 days +14 days) is 100 percent, and the cure rate (7 days +14 days) is 0 percent.
The 34 people in the treatment group of the diclofenac sodium plaster for the Japanese forest pharmacy are shown in the table 6:
TABLE 6 therapeutic results of 34 patients in the Nippon Xiaolin pharmaceutical diclofenac sodium Patch treatment group
Figure BDA0002792913790000161
The diclofenac sodium plaster is a product for treating diseases such as muscle, joint, fascia and ligament injury pain, arthritis and the like in the pharmaceutical production of Japan forest.
Acute joint sprain: the effective rate (1 hour +72 hours) is 100 percent, and the cure rate (1 hour +72 hours) is 0 percent;
acute muscle strain: the effective rate (1 hour +72 hours) is 100 percent, and the cure rate (1 hour +72 hours) is 0 percent;
chronic achilles tendonitis: the effective rate (7 days +14 days) is 0 percent, and the cure rate (7 days +14 days) is 0 percent;
chronic bursitis: the effective rate (7 days +14 days) is 100 percent, and the cure rate (7 days +14 days) is 0 percent;
chronic fasciitis: the effective rate (7 days +14 days) is 25 percent, and the cure rate (7 days +14 days) is 0 percent.
Example 10 of the invention plant emulsion treatment group 34 humans are shown in table 7:
TABLE 7 therapeutic results of 34 human patients treated with the plant emulsion of example 10 of the present invention
Figure BDA0002792913790000162
Figure BDA0002792913790000171
Acute joint sprain: the effective rate (1 hour +72 hours) is 100 percent, and the cure rate (1 hour +72 hours) is 50 percent;
acute muscle strain: the effective rate (1 hour +72 hours) is 100 percent, and the cure rate (1 hour +72 hours) is 0 percent;
chronic achilles tendonitis: the effective rate (7 days +14 days) is 100 percent, and the cure rate (7 days +14 days) is 0 percent;
chronic bursitis: the effective rate (7 days +14 days) is 100 percent, and the cure rate (7 days +14 days) is 0 percent;
chronic fasciitis: the effective rate (7 days +14 days) is 100 percent, and the cure rate (7 days +14 days) is 100 percent.
The experimental results can be seen as follows:
the cure rate of all similar product formulas on the market for muscle and soft tissue injuries is 0%, only the symptom can be relieved, and the rehabilitation process cannot be accelerated for the following reasons:
1.1, common products do not consider skin barrier problems, so that effective ingredients are difficult to permeate;
1.2, after the skin barrier reaches the dermis, the cell intermittence is about 200nm, and the common formula is difficult to effectively permeate;
1.3, the chemical property is only considered when the formula fineness is insufficient, namely prostaglandin E secretion is inhibited through non-steroidal anti-inflammatory drugs, and the nerve sensitivity is reduced without considering local cooling;
1.4, the similar products can not completely play a role in the set injuries without fracture, bone fracture and ligament and tendon laceration, and the symptoms of a patient can not be completely relieved by single-acting components or anesthesia.
The plant emulsion of the invention has the following action principle:
the pH value of the plant emulsion is set to be between 5 and 7, the pH value of the plant emulsion is matched with the pH value of the skin surface, the plant emulsion can rapidly pass through a double-layer lipid structure protected by the skin surface, the double-layer lipid structure on the skin surface is considered, an O/W water-in-oil process is adopted, an oil layer as an outer layer of an effective substance can be rapidly compatible with and permeate the double-layer lipid structure on the skin surface, a holly extract and a mint extract are used for synergistically relieving pain, namely, a neurotransmitter prostaglandin E is adopted for inhibiting, the local temperature is deeply reduced, the nerve sensitivity is further reduced, so that synergistic pain relief is realized, a supercritical high-purification process is adopted to purify the required effective component to be more than 96% or even higher so as to ensure the concentration of the effective component; considering the structure of human skin, the emulsifier with negative ion property and the auxiliary emulsifier are adopted for process manufacturing (most human pathological change cells are in positive charge state), thus the microemulsion quickly passes through the epidermis and then quickly reaches the focus by virtue of charge attraction to realize the local biological missile effect.
According to the invention, the ilex extract and the mint extract are used as main effective components, isopropyl myristate is used as an emulsifier, 1, 3-butanediol is used as an auxiliary emulsifier, both isopropyl myristate and 1, 3-butanediol are negative ion in nature, and polyoxyethylene hydrogenated castor oil is used as an oil phase.
According to the invention, the ilex extract, the mint extract and isopropyl myristate are dissolved in the polyoxyethylene hydrogenated castor oil, then the mixed oil phase, the 1, 3-butanediol and the water are mixed for high-pressure emulsification treatment, and after emulsification is finished, the temperature is rapidly reduced, and a water-in-oil structure is formed by temperature phase control.
The plant emulsion is of a water-in-oil structure, effective molecules can be pulled open by the water-in-oil structure, the phenomenon that the effective molecules are adhered to form macromolecules due to van der Waals force is avoided, a single water-in-oil structure is small in molecule and only dozens of nanometers, the water-in-oil structure can permeate layer by layer quickly through skin, wall breaking is achieved at a focus, the effective molecules act on the focus, the treatment effect is good, the treatment process is fast, and the bioavailability is high.
The active ingredients of the plant emulsion are a wintergreen extract and a mint extract, the main active ingredients of the wintergreen extract are salicylic acid and salicylic acid glycoside, the main active ingredients of the mint extract are menthol and menthone, the high-purity salicylic acid substance has anti-inflammatory and pain-relieving effects, the salicylic acid plays an analgesic effect by inhibiting the synthesis of a local nerve ending transmitter prostaglandin E, the high-purity menthol has high volatility, and the high-purity menthol takes away local tissue heat in the local use volatilization process so as to reduce local temperature, can reduce local tissue exudation after local temperature reduction, and simultaneously reduces nerve ending sensitivity to cooperate with the salicylic acid substance to play an analgesic function; meanwhile, the NE (microemulsion) technology is applied to reduce the particle diameters of two effective substances so that the two effective substances can directly penetrate through the natural barrier of the skin to the dermis and even the joint capsule cavity, thus playing the roles of deep pain relieving and anti-inflammatory and avoiding the adverse reaction brought by the application of simple aconitine, ephedrine and anesthetic.
Menthol in the mint extract serving as the effective component of the plant emulsion can volatilize layer by layer in the penetration, and continuously volatilizes after penetrating to a deep focus to realize the function of locally and deeply cooling, so that the temperature of the local surface and depth is durably reduced, the sensitivity of local nerve endings is reduced, and the rapid pain relieving is realized.
While the preferred embodiments of the present invention have been described in detail, the present invention is not limited to the above embodiments, and various changes can be made without departing from the spirit of the present invention within the knowledge of those skilled in the art.
Many other changes and modifications can be made without departing from the spirit and scope of the invention. It is to be understood that the invention is not to be limited to the specific embodiments, but only by the scope of the appended claims.

Claims (9)

1. The plant emulsion for treating soft tissue injury after sports is characterized by comprising the following components in percentage by weight: 5-15% of a holly extract, 1-6% of a mint extract, 15-20% of polyoxyethylene hydrogenated castor oil, 0.5-3% of isopropyl myristate, 1-5% of 1, 3-butanediol and 51-77.5% of water.
2. The plant emulsion for treating soft tissue injury after sports according to claim 1, wherein the weight percentage of each component is as follows: 8-12% of a holly extract, 2-5% of a mint extract, 16-18% of polyoxyethylene hydrogenated castor oil, 0.5-2% of isopropyl myristate, 1-4% of 1, 3-butanediol and 59-72.5% of water.
3. The plant emulsion for treating soft tissue injury after sports according to claim 2, wherein the weight percentage of each component is as follows: 10% of holly extract, 3.5% of mint extract, 17% of polyoxyethylene hydrogenated castor oil, 1% of isopropyl myristate, 3% of 1, 3-butanediol and 65.5% of water.
4. The botanical emulsion for treating post-exercise soft tissue injury as claimed in claim 3, wherein said extract of ilex purpurea is prepared by: selecting fresh Chinese ilex leaves, cleaning, draining and slicing the Chinese ilex leaves, soaking the Chinese ilex leaves in distilled water serving as a solvent for 10-12 hours, then carrying out steam distillation on the solution in which the Chinese ilex leaves are soaked for 1-2 hours, layering the liquid obtained after the steam distillation, collecting an oil layer, carrying out reduced pressure distillation on the oil layer at the distillation pressure of 0.09MPa, collecting fractions at the temperature of 218-224 ℃ to obtain a Chinese ilex extract, placing the Chinese ilex extract in a brown sample bottle, and storing at the temperature of 4 ℃.
5. The plant emulsion for treating soft tissue injury after sports according to claim 4, wherein the material ratio of the Chinese ilex leaves to the water is 1: 1.
6. the botanical emulsion for treating post-exercise soft tissue injury according to claim 3, wherein the mint extract is prepared by: selecting the overground part of mint, cleaning, draining and slicing the overground part of mint, drying to ensure that the water content is less than 8%, crushing the dried overground part of mint by using a crusher, sieving to obtain mint powder, filling the mint powder into an extraction kettle, and performing supercritical CO extraction2Extracting, collecting extract, placing the extract in brown bottle, and storing at 4 deg.C.
7. The botanical emulsion for treating post-exercise soft tissue injury according to claim 6, wherein the supercritical CO is2The extraction pressure is 8-10 MPa, the temperature is 50-55 ℃, and CO is added2The flow rate is 22-25L/h, and the extraction time is 1-3 h.
8. A method of preparing a plant emulsion for the treatment of soft tissue injury after exercise according to any one of claims 1 to 7, comprising the steps of:
step 1) dissolving 0.5-3% of isopropyl myristate, 5-15% of holly extract and 1-6% of mint extract in 15-20% of polyoxyethylene hydrogenated castor oil, and uniformly stirring until the mixture is completely mixed, wherein the reaction temperature is 43 ℃;
step 2) when the mixture in the step 1) is completely dissolved to be clear, adding the mixture into 51-77.5% of water, uniformly stirring, simultaneously adding 1-5% of 1, 3-butanediol, stirring, heating to 43 ℃, and pressurizing for reaction;
and 3) starting a cold cycle to cool the mixture obtained in the step 2) to 20 ℃, and keeping the whole temperature stable at 23 ℃ after the mixture is continuously cooled for 15-20 minutes to obtain the plant emulsion for treating the soft tissue injury after sports.
9. The method according to claim 8, wherein the stirring speed in step 1) is 40 times/min and the stirring time is 50-60 minutes, the stirring speed in step 2) is 40 times/min and the stirring time is 30-60 minutes, and the pressurizing pressure is 897 bar.
CN202011321031.9A 2020-11-23 2020-11-23 Plant emulsion for treating soft tissue injury after exercise and preparation method thereof Pending CN112353847A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011321031.9A CN112353847A (en) 2020-11-23 2020-11-23 Plant emulsion for treating soft tissue injury after exercise and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011321031.9A CN112353847A (en) 2020-11-23 2020-11-23 Plant emulsion for treating soft tissue injury after exercise and preparation method thereof

Publications (1)

Publication Number Publication Date
CN112353847A true CN112353847A (en) 2021-02-12

Family

ID=74533574

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011321031.9A Pending CN112353847A (en) 2020-11-23 2020-11-23 Plant emulsion for treating soft tissue injury after exercise and preparation method thereof

Country Status (1)

Country Link
CN (1) CN112353847A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103142697A (en) * 2013-03-01 2013-06-12 福建美菰林生物科技有限公司 Pharmaceutical composition for relieving muscular soreness and preparation method thereof
CN111110436A (en) * 2020-01-08 2020-05-08 陕西盘龙药业集团股份有限公司 Nanometer quick-pasting cold compress gel, preparation method thereof and nanometer quick-pasting cold compress gel paste

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103142697A (en) * 2013-03-01 2013-06-12 福建美菰林生物科技有限公司 Pharmaceutical composition for relieving muscular soreness and preparation method thereof
CN111110436A (en) * 2020-01-08 2020-05-08 陕西盘龙药业集团股份有限公司 Nanometer quick-pasting cold compress gel, preparation method thereof and nanometer quick-pasting cold compress gel paste

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
吴文豹: "《颈肩腰腿痛推拿疗法》", 31 January 1991, 同济大学出版社 *
梁呈元等: "薄荷油不同提取方法的比较", 《时珍国医国药》 *
程英武等: "膏摩治疗家兔急性软组织损伤的实验研究", 《北京中医药大学学报》 *
郭鹏等: "从冬青叶中提取冬青油的工艺探讨", 《信阳师范学院学报(自然科学版)》 *

Similar Documents

Publication Publication Date Title
WO2010150245A1 (en) Pharmaceutical and cosmeceutical compositions containing cannabis flower and seed extracts
CN105251011B (en) A kind of spray-filming agent and preparation method thereof for superficial burns
CN102327419A (en) External use medicine for treating wound healing
US10758578B2 (en) Herbal formulations of carnivorous plants and methods for treating inflammation
CN108904588A (en) The antibacterial spray of faint scent cassia bark skin and its production technology
US20200384051A1 (en) Herbal formulations of carnivorous plants and methods for treating inflammation
CN109833431A (en) A kind of bacteriostatic gel and preparation method thereof
CN112353847A (en) Plant emulsion for treating soft tissue injury after exercise and preparation method thereof
CN110269839A (en) A kind of application of cannabidiol CBD and its nano-emulsion in nettle rash or/and preparation for treating rhinitis
CN103007034B (en) Traditional Chinese medicine composition used for treatment of residual second-degree burn wound, and preparation method thereof
CN101112417B (en) Rheum defervescence liniment and method for preparing the same
CN110882332B (en) Antibacterial, anti-inflammatory and antiallergic nasal traditional Chinese medicine composition and preparation method and application thereof
CN109364290A (en) A kind of Lavender liposome liquid adhesive bandage and preparation method thereof
WO2018161890A1 (en) Application of berberine in preparing drug for treating acute soft tissue injury
CN104083406B (en) A kind of compound disinfectant and preparation method thereof
US11229610B2 (en) Cannabinoid and menthol gel compositions, patches and methods
CN111939215A (en) Composition for treating bromhidrosis
KR101206097B1 (en) Composition for promoting the differentiation of human mesenchymal stem cell to adipocytic cells
CN111035597A (en) Bacteriostatic itching-relieving topless drops and preparation method thereof
CN112007075A (en) Compound peppermint oil nanoemulsion composition and preparation method thereof
RU2336868C1 (en) Method of animal wound treatment
CN108686015A (en) It is a kind of to treat dog skin disease Traditional Chinese medicine compound gel agent and its preparation method and application
CN115518111B (en) Chinese herbal compound preparation for treating rhinitis and preparation method thereof
CN106880761A (en) A kind of clinical laboratory's disinfection solution and preparation method thereof
CN107913332A (en) A kind of clinical laboratory combination of Chinese tradiational and Western medicine disinfectant and preparation method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210212